Royal Philips Buys BioTelemetry

Royal Philips Buys BioTelemetry

The medical device giant Royal Philips (NYSE: PHG) is back with a new deal, adding BioTelemetry, Inc. (NYSE: BEAT). The deal is valued at $2.8 billion, consisting of $72.00 per share in cash, or a 16.5% premium to BEAT’s closing price on December 17, 2020. BioTelemetry, formerly known as CardioNet, is a leading provider of remote cardiac diagnostics and monitoring, centralized core laboratory services for clinical trials, remote blood glucose monitoring and original equipment manufacturing for healthcare and clinical research customers. BioTelemetry generated an annualized 2020 revenue of $458 million and annualized 2020 EBITDA of $92.3 million. The acquisition is a strong fit with... Read More »
Boston Scientific Divests BTG Specialty Pharmaceuticals Business

Boston Scientific Divests BTG Specialty Pharmaceuticals Business

In November 2018, Boston Scientific Corporation (NYSE: BSX) purchased BTG plc for $4.8 billion, according to search results in our Healthcare Deal Database. BTG develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases. However, the company also had an acute care pharmaceutical division, which based on recent deal activity, it seemed the medical device giant wasn’t too interested in holding onto the non-medical device portions of BTG. In the fourth quarter of 2019, Boston Scientific sold the pharmaceutical licensing royalties unit of BTG, and last week, the company announced the second divestment. Boston Scientific is selling... Read More »
Royal Philips Buys BioTelemetry

Smith & Nephew Returns to the M&A Market

It’s been over a year since Smith & Nephew plc (NYSE: SNN) announced a transaction, but the medical device manufacturer is back on the acquisition trail. On September 29, the company purchased Integra LifeSciences Holdings Corporation’s (NASDAQ: IART) extremity orthopedics business for $240 million. The business includes a portfolio of devices, implants and instruments for shoulder replacement as well as reconstruction of bone in the hand, wrist and elbow, and foot and ankle. This deal will significantly strengthen Smith & Nephew’s extremities business by adding a combination of a focused sales channel, complementary shoulder replacement and upper and lower extremities... Read More »
Royal Philips Buys BioTelemetry

Varian and Siemens Healthineers Merge in Multi-Billion Dollar Deal

After a slow opening month for the third quarter, the merger between Varian Medical Systems (NYSE: VAR) and Siemens Healthineers AG (XETRA: SHL.DE) might bring some spark to the healthcare M&A market. Siemens Healthineers announced it was purchasing Varian for $16.4 billion, the largest deal of the year so far. Siemens Healthineers will acquire all shares of Varian for $177.50 per share in cash, a premium of approximately 24% to the closing price of Varian’s common stock on July 31, 2020. Varian generated trailing 12-month revenues of $3.2 billion and EBITDA of $536.3 million.  For more than 70 years, Varian has developed, built, and delivered innovative cancer care technologies and... Read More »
Royal Philips Buys BioTelemetry

Medicrea Acquired by Medtronic to Boost Spinal Surgery Portfolio

Medtronic plc (NYSE: MDT) has had a busy 2020, but the global device manufacturer doesn’t seem to be slowing down. On June 15, the company announced it acquired Medicrea (OTCMKTS: MRNTF) for $158.7 million, or $8 a share. This acquisition will strengthen Medtronic’s position as a global innovator in enabling technologies and solutions for spine surgery.   Medicrea leads the design, integrated manufacture, and distribution of more than 30 510(k) cleared implant technologies, utilized in over 175,000 spinal surgeries to date. It has 175 employees worldwide, including 35 employees in New York City. The company also has a modern manufacturing facility in Lyon, France, housing the... Read More »
LeMaitre Acquires New Jersey-based Medical Device Firm

LeMaitre Acquires New Jersey-based Medical Device Firm

LeMaitre Vascular (NASDAQ: LMAT), a Massachusetts-based medical device manufacturer, announced a new addition to its portfolio. The company has purchased Artegraft, Inc., which processes and sells biologic vascular grafts that are derived from bovine carotid arteries and are implanted primarily in hemodialysis access patients. Its products are marketed under the brand Artegraft and are sold only in the U.S. Artegraft generated trade sales of $15.6 million and estimated hospital-level sales of $18.6 million during the twelve-month period ended May 31, 2020. Artegraft’s unit sales grew by 10% in 2019. LeMaitre purchased Artegraft for a total of $72.5 million in cash, with $65 million upfront... Read More »